Loading…
Employees: 327
Size Ceribell (CBLL) is a United States Health Care company (Medical Specialties) with a market value of $1.03B, the 2226th largest of 3,117 United States companies the cockpit tracks. Shares closed at $26.59 on 6 Nov 2026.
Performance Over six months the shares gained 31.6%, against -14.2% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 31.3% over the last twelve months (peer median +6.4%); the operating margin is -69.8% (peer median 7.2%).
Valuation It trades at 8.6× enterprise value to sales against a peer median of 4.5× (6th most expensive of 20).
Short interest Short interest is 5.6% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $109M | $89.1M | $65.4M | $45.2M | $25.9M |
| Revenue growth | — | +36% | +45% | +74% | — |
| Gross profit | $97.0M | $78.3M | $56.8M | $38.2M | $21.5M |
| EBITDA | -$74.8M | -$57.1M | -$38.6M | -$29.2M | -$35.5M |
| Net income | -$73.9M | -$53.4M | -$40.5M | -$29.5M | -$37.2M |
| Free cash flow | -$56.4M | -$41.7M | -$36.7M | -$30.1M | -$32.5M |
| Capital expenditure | $2.36M | $1.52M | $1.60M | $1.76M | $1.40M |
| Total debt | $21.6M | $22.3M | $22.0M | $14.2M | $18.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CBLL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.9% | +0.3% | 3rd highest of 21 |
| 6-month return | +31.6% | -14.2% | 4th highest of 20 |
| Distance from 52-week high | -8.0% | -34.7% | 2nd highest of 21 |
| Revenue growth (TTM) | +31.3% | +6.4% | 3rd highest of 20 |
| Operating margin | -69.8% | 7.2% | 2nd lowest of 20 |
| EV / Sales | 8.6× | 4.5× | 6th most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | 8.6× | n/a | n/a |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 1.6× | 5.2% | +3.6% |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 2.7× | 7.7% | -2.9% |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 12.8× | n/a | n/a |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | 2.1× | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 12% | 3.4× | 12.4% | +12.9% |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 2.8× | n/a | n/a |
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -59% | 26.9× | n/a | n/a |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 7% | 1.0× | -2.3% | +3.6% |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | 4.5× | n/a | n/a |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 15.6× | 40.1% | +12.4% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 8.0× | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 2.5× | 7.2% | +12.1% |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 5.2× | 6.5% | +10.3% |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 11.7× | 19.1% | +21.5% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | 11.7× | n/a | n/a |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | 3.4× | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 5.6× | n/a | n/a |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 3.4× | 3.1% | +12.7% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 5.8× | 1.5% | +9.9% |